Core Viewpoint - The recent supply shortage and price increase of the Alzheimer's drug Ganluo Sodium (Jiuqi Yi) have raised concerns among patients and the public, prompting discussions about its availability and pricing [1][2][5]. Group 1: Supply Issues - Multiple regions, including Beijing, Shanghai, Guangdong, Shandong, and Heilongjiang, are experiencing shortages of Ganluo Sodium, with patients reporting difficulties in obtaining the medication [2][3]. - The manufacturer, Green Valley (Shanghai) Pharmaceutical Technology Co., has acknowledged the supply issues and is in communication with relevant authorities to address the situation [1][5]. - Over 6,000 patients have registered their demand for the drug amid the supply crisis [5]. Group 2: Price Increases - Online prices for Ganluo Sodium have surged significantly, with reports indicating a rise from approximately 300 yuan to over 540 yuan per box within a month [2][3]. - Various online platforms, including Taobao and JD.com, show prices ranging from 425 yuan to 699 yuan per box, reflecting the impact of the supply shortage on pricing [3][5]. - The company has stated that it is aware of the rapid price increases in some self-paid purchasing channels and is working to mitigate this issue [5]. Group 3: Drug Background and Controversy - Ganluo Sodium was conditionally approved for marketing in November 2019, becoming the first new drug for Alzheimer's disease approved globally since 2003 [6][9]. - The drug has been included in the national medical insurance directory and has benefited over 500,000 patients since its launch [6]. - Despite its approval, the drug has faced criticism regarding its efficacy, with ongoing clinical trials required to confirm its long-term safety and effectiveness [6][7]. Group 4: Clinical Research and Development - Green Valley has reported positive mid-term results from post-marketing clinical studies, showing cognitive and daily living improvements in patients after one year of treatment [7]. - The international multi-center Phase III clinical trial for Ganluo Sodium was prematurely terminated in 2022 due to funding issues and the impact of the pandemic, with plans to restart when conditions allow [8][9]. - The pharmaceutical industry faces significant challenges in Alzheimer's drug development, with a high failure rate and substantial investment required, highlighting the ongoing need for effective treatments [9][10].